Summary of minutes of EUCAST Steering Committee Meeting  
Madrid, Spain, 24-25 September 2012

Attending
Dr Petra Apfalter PA EUCAST Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Chairperson Spain
Dr Christian Giske CG SRGA Sweden
Dr Robin Howe RH BSAC United Kingdom
Prof Gunnar Kahlmeter GK Clinical Data Co-ordinator Sweden
Prof Luis Martínez-Martínez LM EUCAST Spain
Dr Johan W. Mouton JM CRG The Netherlands
Dr Robert Skov RS EUCAST Denmark
Dr Martin Steinbakk MS NWGA Norway

Apologies
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Prof Claude-James Soussy CS CA-SFM France

1 Chairman’s welcome RH represented BSAC in place of AM.

2 Minutes of meeting of 9-10 July 2012 With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of 9-10 July 2012 Documents were distributed as agreed.

4 New agents
Ceftaroline breakpoints have been posted in the news section of the EUCAST website. The current status of several other new agents was discussed.

5 EUCAST rationale documents Several documents are still to be completed.

6 Subcommittees
Antifungal susceptibility testing: No new information.
Detection of resistance mechanisms of clinical and/or epidemiological importance: A first draft of a report is close to completion.

7 Breakpoint tables v. 3.0 A draft was reviewed in detail.

8 Other breakpoint issues
Urinary breakpoints for fluoroquinolones with enterococci and for Enterobacteriaceae with amoxicillin-clavulanate are being considered.
Data relating N. meningitidis penA mutations with penicillin MICs are being collected.
A rationale document for Acinetobacter spp. and sulbactam is being drafted.
β-lactamase-producing enterococci have been reported in Italy, but they remain rare.
A joint EUCAST-CLSI group on colistin breakpoints is being set up.
Aminoglycoside breakpoints will be reviewed as Pk/Pd data are now available.
Proposals for changes to breakpoints for cefuroxime axetil and H. influenzae are being reviewed.
Problems with MIC distributions for ticarcillin-clavulanic acid and Pseudomonas spp are being investigated.

9 Organisms without EUCAST breakpoints
Comments from the wide consultation on Campylobacter spp. were discussed.
Data on Legionella spp. are being collected.
Comments from the wide consultation on P. multocida were discussed.
Data on susceptibility testing of B. cepacia were discussed and a guidance note will be produced.
Data on susceptibility testing of Actinomycetes spp. were reviewed.
Work on breakpoints and susceptibility testing methods for Corynebacterium spp. are in progress.
MIC distributions for Nocardia spp. are being collected but few are available.
Work has started on breakpoints and methods for Pseudomonas spp. other than P. aeruginosa.
10 EUCAST methods
QC tables have been updated and version 2.1 is on the website.
A minor discrepancy between the disk diffusion slideshow and method description will be corrected.
The EUCAST discussion document on the agar dilution method, which is referenced in the ISO MIC document, is on the EUCAST website.
BioMérieux now state in Etest packaging that MH-F is a validated medium.
EUCAST breakpoints are now included in WHONET.

11 Implementation of EUCAST breakpoints
A publication on implementation will be prepared when a EUCAST survey is completed.
The EUCAST website file on compliance of manufacturers has been updated.
Breakpoint tables are to be translated into Japanese and Lithuanian.
NACs are being set up and EUCAST breakpoints implemented in several countries.

12 EUCAST website
There are proposals for a "trans-Atlantic" website for MIC distributions and ECOFFs based on the EUCAST MIC distribution website.
A summary of EUCAST "highlights" will be posted on the ESCMID website after each Steering Committee meeting.

13 Publications
Papers explaining ECOFFs and "reporting as found" are being worked on.

14 Dosages in breakpoint tables
Inclusion of a table with more detailed data on dosing with breakpoint tables is being considered.

15 EUCAST SOPs
SOPs on interaction of the Steering Committee with NACs and revision of breakpoints are close to completion.

16 ESCMID
The EUCAST-ESGARS Postgraduate Course on susceptibility testing and surveillance will be held in Madrid, September 2012.
There will be an ESCMID, EPFSG, EUCAST, ESGARS conference on redevelopment of antibiotics in Vienna, October 2014.

17 EMA
Various EMA-related issues were discussed.

18 CLSI
Revised breakpoints are the same as EUCAST breakpoints for pneumococci and tetracycline/doxycycline.

19 ECDC
ECDC national focal points will be included in EUCAST consultations.

20 List of agents recommended for testing
Proposals are being developed.

21 ISO standard for MH medium
The ISO working group is producing a draft that will be released for voting by national standards organisations.

22 Topical agents
Comments from the wide consultation on breakpoints for topical agents were discussed. A table will be included with breakpoint tables.

23 Any other business
None.

24 Next meetings
12-13 November 2012, Rome, Italy.
4-5 February 2013, Brussels, Belgium
30 April -1 May 2013, Berlin, Germany.
8-9 July 2013, Copenhagen, Denmark.